VRDN FY 2019 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-46.8% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$42M-941.0% margin

Net Income

-$42M-938.6% margin

EPS (Diluted)

$-20.31

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$30M

Total Liabilities

$15M

Stockholders' Equity

$16M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$8M	-46.8%
Gross Profit	$4M	-$22M	+120.2%
Operating Income	-$42M	-$33M	-26.9%
Net Income	-$42M	-$33M	-28.0%